EDGAR Filing Documents for 0000886163-13-000060

Form 8-K - Current report:

SEC Accession No. 0000886163-13-000060

Filing Date

2013-06-20

Accepted

2013-06-20 08:37:25

Documents

Period of Report

2013-06-20

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	ligand-8xkxbvfamendedlette.htm	8-K	29662
2	FIRST AMERNDMENT TO 2006 PREFERRED SHARES RIGHTS AGREEMENT	ligand-firstamendmentto200.htm	EX-4.1	17787
3	BVF LETTER OF AGREEMENT	ligand-bvfletterofagreemen.htm	EX-10.1	73468
4	PRESS RELEASE BVF OWNERSHIP INCREASE	ligand-pressreleasere_bvow.htm	EX-99.1	13201
5		ligandlogo.jpg	GRAPHIC	36525
	Complete submission text file	0000886163-13-000060.txt		185953

Mailing Address 11119 NORTH TORREY PINES ROAD SUITE 200 LA JOLLA CA 92037

Business Address 11119 NORTH TORREY PINES ROAD SUITE 200 LA JOLLA CA 92037 858-550-7500

LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)